ReviewAnnual review of pharmacology and toxicology2014
Understanding and modulating mammalian-microbial communication for improved human health.
Review in Annual review of pharmacology and toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications.International journal of molecular sciences · 2025Review
- Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments.Pharmaceutics · 2025Review
- Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals.BMC medicine · 2024Observational
- Glucuronic acid confers colonization advantage to enteric pathogens.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Integrating the gut microbiome and pharmacology.Science translational medicine · 2024Review
- Estrobolome and Hepatocellular Adenomas-Connecting the Dots of the Gut Microbial β-Glucuronidase Pathway as a Metabolic Link.International journal of molecular sciences · 2023Review
- Characterizing the metabolic effects of the selective inhibition of gut microbial β-glucuronidases in mice.Scientific reports · 2022Article
- A structural metagenomics pipeline for examining the gut microbiome.Current opinion in structural biology · 2022Review
- NSAID-Gut Microbiota Interactions.Frontiers in pharmacology · 2020Review
- Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Review
- Active site flexibility revealed in crystal structures of Parabacteroides merdae β-glucuronidase from the human gut microbiome.Protein science : a publication of the Protein Society · 2018Article
- Three structurally and functionally distinct β-glucuronidases from the human gut microbeThe Journal of biological chemistry · 2018Article
- Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases.World journal of hepatology · 2017Review
- An Atlas of β-Glucuronidases in the Human Intestinal Microbiome.Structure (London, England : 1993) · 2017Article
- Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.Current pharmacology reports · 2017Article
- An in silico pan-genomic probe for the molecular traits behind Lactobacillus ruminis gut autochthony.PloS one · 2017Article
- The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.The Yale journal of biology and medicine · 2016Review
- Review
- The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.Nature reviews. Microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The fact that the bacteria in the human gastrointestinal (GI) tract play a symbiotic role was noted as early as 1885, well before we began to manage microbial infections using antibiotics. However, even with the first antimicrobial compounds used in humans, the sulfa drugs, microbes were recognized to be critically involved in the biotransformation of these therapeutics. Thus, the roles played by the microbiota in physiology and in the management of human health have long been appreciated. Detailed examinations of GI symbiotic bacteria that started in the early 2000s and the first phases of the Human Microbiome Project that were completed in 2012 have ushered in an exciting period of granularity with respect to the ecology, genetics, and chemistry of the mammalian-microbial axes of communication. Here we review aspects of the biochemical pathways at play between commensal GI bacteria and several mammalian systems, including both local-epithelia and nonlocal responses impacting inflammation, immunology, metabolism, and neurobiology. Finally, we discuss how the microbial biotransformation of therapeutic compounds, such as anticancer or nonsteroidal anti-inflammatory drugs, can be modulated to reduce toxicity and potentially improve therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.